Published Jun 15, 2021



PLUMX
Almetrics
 
Dimensions
 

Google Scholar
 
Search GoogleScholar
Downloads


Fabian Orozco-Lopez

Liliana Rocío Guerrero-Villalobos

Paola Andrea Cuervo-Prado

##plugins.themes.bootstrap3.article.details##

Abstract

A computer-assisted approach was used to model and study privileged heterocyclic scaffolds containing dihydropyrazole, pyrimidin-2-amine, and thiazolidin-4-one moieties (hybrid pharmacophores) to obtain novel and promising antimicrobial prototype molecules. Main bioavailability descriptors were determined in order to assess the drug-likeness of the designed compounds and to pre-filter eleven compounds exhibiting the best profiles, thus passing to molecular docking study against a key penicillin-binding protein type-3 from enterotoxygenic E. coli. Seven structures were chosen by their
energies of affinity and docking interactions with key residues in the active site of the receptor. Seven compounds with the highest docking scores belonging to the series of chalcones, dihydropyrazoles, aminopyrimidines, and thiazolidin-4-ones were prepared via condensation or cyclocondensation reactions. The structural elucidation of the final products was carried out by infrared spectra analysis and NMR experiments. Such molecular hybrids considered as potential hits in the search for new antibacterial compounds will be tested in vitro in further studies.

Keywords

PBP-3 inhibitors, hybrid pharmacophores, in silico screening, dihydropyrazoles, pyrimidin-2-amines, thiazolidin-4-ones

References
[1] Cuellar LE, Infecciones en huéspedes inmunocomprometidos. Revista Medica Herediana, 24: 156-161, 2013.

[2] Bourgeois AL, Wierzba TF, Walker RI. (2016). Status of vaccine research and development for enterotoxigenic Escherichia coli. Vaccine. 34 (26): 2880–2886, 2016.
doi: 10.1016/j.vaccine.2016.02.076

[3] Gupta SK, Keck J, Ram PK, Crump JA, Miller MA, Mintz ED. Analysis of Data Gaps Pertaining to Enterotoxigenic Escherichia coli Infections in Low and Medium Human Development Index Countries, 1984-2005. Epidemiology and Infection. 136 (6): 721–738, 2008.
doi: 10.1017/S095026880700934X

[4] Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. The Lancet. 382 (9888): 209–222, 2013.
doi: 10.1016/s0140-6736(13)60844-2

[5] Ochoa TJ, Contreras CA. Enteropathogenic Escherichia coli infection in children. Current Opinion in Infectious Diseases. 24: 478–483, 2011.
doi: 10.1097/QCO.0b013e32834a8b8b

[6] Contreras CA, Ochoa TJ, Lacher DW, et al. Allelic variability of critical virulence genes (eae, bfpA and perA) in typical and atypical enteropathogenic Escherichia coli in Peruvian children. J. Med Microbiol. 59: 25–31, 2010.
doi: 10.1099/jmm.0.013706-0

[7] World Health Organization. (2016). Antibiotic resistance. Fact sheet.

[8] Vardanyan R, Hruby V. Synthesis of Best-Seller Drug. University of Arizona, Academic Press, Tucson, AZ, pp 847, 2016.

[9] Reguero M, Barreto E, Jimenez F. Relacion estructura quimica actividad biológica. Una revisión retrospectiva. Revista Colombiana de de Ciencias Quimico-farmaceuticas, 17: 81-84, 1989.
doi: 10.15446/rcciquifa

[10] Amábile-Cuevas C. In many ways, the fight against antibiotic resistance is already lost; preventing bacterial disease requires thoughtful new approaches. Am. Sci, 91: 138-149, 2003.

[11] Marovac J. Investigación y desarrollo de nuevos medicamentos: de la molécula al farmaco. Revista médica de Chile, 129 (1): 99-106, 2001.
doi: 10.4067/S0034-98872001000100015

[12] Escalona J, Carrasco R, Padrón J. Introducción al diseño racional de fármacos. Editorial Universitaria, Ciudad de la Habana, Cuba, pp 12-17, 2008.

[13] Sainsbury S, Bird L, Rao V, Shepherd S, Stuart D, Hunter W, Ren J. Crystal Structures of Penicillin-Binding Protein-3 from Pseudomonas aeruginosa: Comparison of Native and Antibiotic-Bound Forms. J. Mol. Biol. 405: 173-184, 2011.
doi: 10.1016/j.jmb.2010.10.024

[14] Kong KF, Schneper L, Mathee K. Beta-lactam antibiotics: from antibiosis to resistance and bacteriology. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 118(1): 1–36, 2010.
doi: 10.1111/j.1600-0463.2009.02563.x

[15] Protein Data Bank (PDB). Available at: https://www.rcsb.org/structure/4BJP. [Accessed Nobember 6, 2020].

[16] Sauvage E, Derouaux A, Fraipont C, Joris MHR. et al. Crystal Structure of Penicillin-Binding Protein 3 (PBP3) from Escherichia coli. PLoS ONE. 9(5): e98042, 2014.
doi: 10.1371/journal.pone.0098042

[17] Ghuysen JM. Serine beta-lactamases and penicillin-binding proteins. Annu. Rev. Microbiol. 45: 37-67, 1991.
doi: 10.1146/annurev.mi.45.100191.000345

[18] Farghaly A, Esmail S, Abdel-Zaher A, Bdel-Hafez A, El-Kashef H. Bioorg. Med. Chem. 22: 2166, 2014.
doi: 10.1016/j.bmc.2014.02.019

[19] Salum L, Mascarello A, Canevarolo R, Altei W, Laranjeira A, Neuenfeldt P, Stumpf T. Eur. J. Med. Chem. 96: 504, 2015.
doi: 10.1016/j.ejmech.2015.02.041

[20] Hammad SG, El-Gazzar MG, Abutaleb NS, Li D, Ramming I, Shekhar A, Abdel-Halim M, Elrazaz EZ, Seleem MN, Bilitewski U, Abouzid KAM, El-Hossary EM. Bioorg. Chem. 95: 103517, 2020.
doi: 10.1016/j.bioorg.2019.103517

[21] Abo-Ashour MF, Eldehna WM, George RF, Abdel-Aziz MM, Elaasser MM, Gawad NMA, Gupta A, Bhakta S, Abou-Seri SM. Eur. J. Med. Chem. 160: 49-60, 2018.

[22] Rashid M, Husain A, Shaharyar M, Mishra R, Hussain A, Afzal O. Eur. J. Med. Chem. 83: 630, 2014.
doi: 10.1016/j.ejmech.2014.06.033

[23] Kumar D, Singh SP. Heterocycles, 63(1): 145, 2004.
doi: 10.3987/REV-03-569

[24] Khunt RC, Khedkar VM, Chawda RS, Chauhan NA, Parikh AR, Coutinho EC. Bioorg. Med. Chem. Lett. 22: 666-678, 2012.
doi: 10.1016/j.bmcl.2011.10.059

[25] Shaquiquzzaman M, Khan S, Amir M, Alam M. Saudi. Pharm. J. 20: 149-154, 2012.
doi: 10.1016/j.jsps.2011.09.007

[26] Premnath D, Indiraleka M. Asian. J. Med. Anal. Chem. 1: 27-32, 2014.

[27] Taj T, Kamble R, Gireesh T, Hunnur R, Margankop S. Eur. J. Med. Chem. 46: 4366-73,2011.
doi: 10.1016/j.ejmech.2011.07.007

[28] Kumar H, Saini D, Jain S, Jain N. Eur. J. Med. Chem. 70: 248-258, 2013.
doi: 10.1016/j.ejmech.2013.10.004

[29] Spring D. Diversity-oriented synthesis; a challenge for synthetic chemists. Org. Biomol. Chem. 1: 3867-3870, 2003.
doi: 10.1039/B310752N

[30] Moreno-Díaz H, Villalobos-Molina R, Ortiz-Andrade R, Díaz-Coutiño D, Medina-Franco JL, Webster SP, et al. Bioorg. Med. Chem. Lett. 18: 2871–2877, 2008.
doi: 10.1016/j.bmcl.2008.03.086

[31] Navarrete-Vázquez G, Moreno-Diaz H, Aguirre-Crespo F, León-Rivera I, Villalobos-Molina R, Muñoz-Muñiz O, et al. Bioorg. Med. Chem. Lett. 16: 4169-4173, 2006.
doi: 10.1016/j.bmcl.2006.05.082

[32] Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. admetSAR: A Comprehensive Source and Free Tool for Assessment. J. Chem. Inf. Model. 52: 3099-3105, 2012.
doi: 10.1021/ci300367a

[33] Sashidhara KV, Rosaiah JN, Kumar A. Synth. Commun. 39: 13, 2288-2296, 2009.
doi: 10.1080/00397910802654724

[34] Hodge H, Sterner J. Am. Ind. Hyg. Assoc. Q. 10: 94-97, 1949.

[35] Durst HD, Gokel GW. Química Orgánica Experimental. Reverté S.A., Barcelona, España, pp 325-327, 1985.

[36] Jawale DV, Pratap UR, Bhosale MR, Mane RA. J. Het. Chem. 53: 1626-1630, 2016.
doi: 10.1002/jhet.673

[37] Qiya Z, Hong XH, Suhui W, Shuajiang T, Liangce R. Synth. Commun. 39: 516-522, 2009.
doi: 10.1080/00397910802399932
How to Cite
Orozco-Lopez, F., Guerrero-Villalobos, L. R., & Cuervo-Prado, P. A. (2021). Computer-aided design, synthesis, and characterization of molecular hybrids of dihydropyrazoles, aminopyrimidines, and thiazolidin-4-ones as potential inhibitors of the penicillin-binding protein 3 (PBP-3) of Escherichia coli. Universitas Scientiarum, 26(1), 17–35. https://doi.org/10.11144/Javeriana.SC26-1.cads
Section
Química Orgánica / Organic Chemistry / Química Orgânica